Prime Medicine Inc. Common Stock (PRME)

About PRME

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

146

Website

primemedicine.com/

Fundamentals

1-day range

$3.29$3.59

Market cap

$532.82M

P/E (trailing)

—

P/E (forward)

-4.00

EPS (trailing)

$-1.09

Dividend yield

—

Beta

2.34

Avg. volume

3.32M

Forecasts

10 analyst ratings

Prime Medicine Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PRME

  Prime Medicine Inc. Common Stock

  $3.62

  ▼ 0.69%
  Market cap $532.82MP/E —
  $2.67$6.94
• AUTL

  Autolus Therapeutics plc American Depositary Share

  $2.34

  ▼ 1.06%
  Market cap $532.31MP/E —
  $1.18$2.58
• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $528.15MP/E —
  $5.37$17.58
• ZURA

  Zura Bio Limited Class A Ordinary Shares

  $5.73

  ▼ 2.05%
  Market cap $542.44MP/E —
  $1.88$7.44
• FDMT

  4D Molecular Therapeutics Inc. Common Stock

  $14.65

  ▼ 1.74%
  Market cap $551.51MP/E —
  $5.97$16.93
• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $570.23MP/E —
  $14.39$39.53
• PROK

  ProKidney Corp. Class A Ordinary Shares

  $1.84

  ▲ 1.10%
  Market cap $495.38MP/E —
  $1.3$3.48

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
  benzinga · 8/19/2026
• Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
  Benzinga · 8/19/2026
• BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
  Benzinga · 8/19/2026
• Prime Medicine: Soon In The Clinic
  SeekingAlpha · 8/15/2026
• Prime Medicine: An Initial Prognosis
  SeekingAlpha · 8/11/2026
• HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target
  Benzinga · 8/10/2026
• Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate
  Benzinga · 8/6/2026

• Chung Wendy · June 5, 2026 · Grant

  75.0K
• Cahill Thomas · June 5, 2026 · Grant

  75.0K
• Michael Aaron Kelly · June 5, 2026 · Grant

  75.0K
• Marrazzo Jeffrey D · June 5, 2026 · Grant

  75.0K
• David P. Schenkein · June 5, 2026 · Grant

  75.0K
• Foster-Cheek Kaye I · June 5, 2026 · Grant

  75.0K
• Robert Nelsen · June 5, 2026 · Grant

  75.0K
• Makhni Svetlana Ni · April 16, 2026 · Grant

  800.0K

Institutional Ownership

March 31, 2026

Total shares held

97.04M

Total value held

$311.91M

Institutional holders

185